InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference
09 janv. 2020 07h30 HE
|
InflaRx N.V.
JENA, Germany, Jan. 09, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Second Quarter 2019 Financial & Operating Results
14 août 2019 16h05 HE
|
InflaRx N.V.
IFX-1 in Hidradenitis Suppurativa did not meet the primary endpoint; trial ongoing - multiple efficacy signals for high-dose group identifiedFirst patient treated in Pyoderma Gangraenosum phase IIa...
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
18 juil. 2019 16h01 HE
|
InflaRx N.V.
IFX-1 treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in HSIFX-1 suppressed C5a levels dose dependently and exhibited a favorable safety...
InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
13 juin 2019 09h00 HE
|
InflaRx N.V.
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative...
InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
05 juin 2019 07h49 HE
|
InflaRx N.V.
IFX-1 did not demonstrate a statistically significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 as primary endpoint IFX-1 treatment achieved a maximum...
InflaRx Reports First Quarter 2019 Financial & Operating Results
23 mai 2019 08h00 HE
|
InflaRx N.V.
IFX-1: New long-term efficacy data from Phase IIa clinical trial in Hidradenitis Suppurativa presented; approval granted to initiate Phase IIa trial in Canada in Pyoderma Gangraenosum; first patient...
InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe
14 mai 2019 08h00 HE
|
InflaRx N.V.
JENA, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx Full Year 2018 Financial & Operating Results
28 mars 2019 08h30 HE
|
InflaRx N.V.
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1Start of three Phase II trials for IFX-1 in two serious inflammatory diseasesExpansion of our...
InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
27 févr. 2019 08h30 HE
|
InflaRx N.V.
Third autoimmune disease being evaluated with IFX-1 Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers JENA, Germany, Feb. 27, 2019 (GLOBE NEWSWIRE) --...
Richard Brudnick to Join InflaRx Board of Directors
14 févr. 2019 08h30 HE
|
InflaRx N.V.
JENA, Germany, Feb. 14, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...